Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center
Yıl: 2021 Cilt: 22 Sayı: 1 Sayfa Aralığı: 61 - 67 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2021.45202 İndeks Tarihi: 16-06-2021
Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center
Öz: Introduction: Insulinoma is the most common functionalneuroendocrine tumor of the pancreas. There are differentmethods for the preoperative localization of insulinoma, suchas Computed Tomography (CT) scan, Magnetic ResonanceImaging and Endoscopic Ultra Sonography (EUS). In this study,we report on the clinicopathological features of insulinoma in43 patients.Methods: The hospital records of 43 patients with suspicion ofinsulinoma based on biochemical diagnostic criteria, referredto İmam Khomeini Complex Hospital, Tehran, Iran between2006 and 2016, were reviewed retrospectively.Results: Of the 43 studied patients, 28 were female. The meanage of the patients was 45.4±13.3 years. The most frequentclinical presentation of insulinoma was neurogenic andneuroglycopenic symptoms (81.4%). Mean glucose, insulin,and C-peptide in patients with hypoglycemic crisis were39.13±13.15 mg/dL, 32.15±32.53 μUI/mL, and 4.77±2.88ng/mL, respectively. Mean tumor size was 2.13±1.22 cm. Themost common site of insulinoma was the tail of the pancreas.Surgery was the treatment of choice and performed in 31patients. Of 21 tumors studied microscopically, 7 were invasive.Conclusion: In non-diabetic patients with manifestationsof hypoglycemia, a diagnosis of insulinoma should beconsidered. During the past decade, the diagnostic delay forinsulinoma has been reduced in our country by improvingimaging technologies. EUS and CT scan are the best modalitiesfor localization and size measurement of insulinoma. Tumorsize has decreased compared with pre
Anahtar Kelime: İnsülinoma: Üçüncül Bir Merkezdeki Klinikopatolojik Özelliklerin Spektrumu
Öz: Amaç: İnsülinoma pankreasın en sık görülen fonksiyonel nöroendokrin tümörüdür. Bilgisayarlı Tomografi (BT) tarama, Manyetik Rezonans Görüntüleme ve Endoskopik Ultrasonografi (EUS) gibi insülinomaların preoperatif lokalizasyonu için farklı yöntemler vardır. Bu çalışmada 43 hastada insülinomun klinikopatolojik özellikleri sunulmaktadır. Yöntemler: 2006-2016 yılları arasında Tahran, İran’da İmam Humeyni Kompleks Hastanesi’ne atıfta bulunulan biyokimyasal tanı kriterlerine göre insülinoma şüphesi olan 43 hastanın retrospektif olarak hastane kayıtları incelendi. Bulgular: Çalışılan 43 hastanın 28’i kadındı. Hastaların ortalama yaşı 45,4±13,3 idi. İnsülinomun en klinik görünümü nörojenik ve nöroglikopenik semptomlardı (%81,4). Hipoglisemik kriz hastalarında ortalama glikoz, insülin ve C-peptit sırasıyla; 39,13±13,15 mg/dL, 32,15±32,53 μUI/mL ve 4,77±2,88 ng/ mL idi. Ortalama tümör boyutu 2,13±1,22 cm idi. En yaygın insülinoma bölgesi pankreas kuyruğuydu. Cerrahi tedavi tercih edildi ve 31 hastaya uygulandı. Mikroskobik incelemeli 21 tümörden 7’si invazivdi. Sonuç: Hipoglisemi belirtileri olan diyabetik olmayan hastalarda insülinoma tanısı düşünülmelidir. Son on yılda, görüntüleme teknolojilerini geliştirerek ülkemizde insülinomun tanısal gecikmesi azalmıştır. EUS ve BT taraması insülinoma lokalizasyonu ve boyut ölçümü için en iyi yöntemlerdir. Muhtemelen tanıdaki gecikmenin azalması nedeniyle tümör boyutu önceki on yıllara göre azalmıştır
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Khagi S, Saif MW. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease. Curr Opin Oncol 2015; 27: 38-43.
- 2. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 691-703.
- 3. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015; 50: 58- 64.
- 4. Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, Tretli S, Bergestuen DS, Hansen S. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology 2017; 104: 1-10.
- 5. Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol 2011; 103: 169-74.
- 6. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61: 113-32.
- 7. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma- -incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66: 711-9.
- 8. Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? Clin Endocrinol (Oxf) 2009; 70: 512-5.
- 9. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-81.
- 10. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int 2010; 9: 234-41.
- 11. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol 2010; 6: 229-37.
- 12. Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 2014; 170: 147-57.
- 13. Cheng Y, Zhan H, Wang L, Xu J, Zhang G, Zhang Z, et al. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. Front Med 2016; 10: 444-50.
- 14. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, et al. A Clinicopathological Study of Malignant Insulinoma in a contemporary series. Pancreas 2017; 46: 48-56.
- 15. Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, et al. Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland. Int J Endocrinol 2018; 2018: 2059481.
- 16. Larijani B, Aghakhani S, Lor SS, Farzaneh Z, Pajouhi M, Bastanhagh MH. Insulinoma in Iran: a 20-year review. Ann Saudi Med 2005; 25: 477-80.
- 17. Goh BK, Ooi LL, Cheow PC, Tan YM, Ong HS, Chung YF, et al. Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years. J Gastrointest Surg 2009; 13: 1071-7.
- 18. Tsang YP, Lang BH, Shek TW. Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg 2016; 86: 706-10.
- 19. Iglesias P, Lafuente C, Martín Almendra MÁ, López Guzmán A, Castro JC, Díez JJ. Insulinoma: A multicenter, retrospective analysis of three decades of experience (1983-2014). Endocrinol Nutr 2015; 62: 306-13.
- 20. Hackert T, Hinz U, Fritz S, Strobel O, Schneider L, Hartwig W, et al. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg 2011; 396: 1197-203.
- 21. Vig S, Lewis M, Foster KJ, Stacey-Clear A. Lessons to be learned: a case study approach insulinoma presenting as a change in personality. J R Soc Promot Health 2001; 121: 56-61.
- 22. Marek B, Kajdaniuk D, Kos-Kudła B, Foltyn W, Borgiel-Marek H, Matyja V, et al. Insulinoma: diagnosis and treatment. Endokrynol Pol 2007; 58: 58-62.
- 23. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94: 709-28.
- 24. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, et al. Localization of insulinomas to regions of the pancreas by intra arterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab 2009; 94: 1074-80.
- 25. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19: 783-98.
- 26. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43: 675-86.
- 27. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-8.
- 28. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
- 29. Taye A, Libutti S. Diagnosis and management of insulinoma: current best practice and ongoing developments. Research and Reports in Endocrine Disorders 2015; 5: 125-33.
- 30. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19: 829-37.
- 31. B Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris) 2013; 74: 523-33.
| APA | Ahmadi P, Shirzad N, Shahsiah R, Hemmatabadi M (2021). Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. , 61 - 67. 10.4274/imj.galenos.2021.45202 |
| Chicago | Ahmadi Pouria,Shirzad Nooshin,Shahsiah Reza,Hemmatabadi Mahboobeh Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. (2021): 61 - 67. 10.4274/imj.galenos.2021.45202 |
| MLA | Ahmadi Pouria,Shirzad Nooshin,Shahsiah Reza,Hemmatabadi Mahboobeh Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. , 2021, ss.61 - 67. 10.4274/imj.galenos.2021.45202 |
| AMA | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. . 2021; 61 - 67. 10.4274/imj.galenos.2021.45202 |
| Vancouver | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. . 2021; 61 - 67. 10.4274/imj.galenos.2021.45202 |
| IEEE | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M "Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center." , ss.61 - 67, 2021. 10.4274/imj.galenos.2021.45202 |
| ISNAD | Ahmadi, Pouria vd. "Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center". (2021), 61-67. https://doi.org/10.4274/imj.galenos.2021.45202 |
| APA | Ahmadi P, Shirzad N, Shahsiah R, Hemmatabadi M (2021). Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. İstanbul Medical Journal, 22(1), 61 - 67. 10.4274/imj.galenos.2021.45202 |
| Chicago | Ahmadi Pouria,Shirzad Nooshin,Shahsiah Reza,Hemmatabadi Mahboobeh Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. İstanbul Medical Journal 22, no.1 (2021): 61 - 67. 10.4274/imj.galenos.2021.45202 |
| MLA | Ahmadi Pouria,Shirzad Nooshin,Shahsiah Reza,Hemmatabadi Mahboobeh Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. İstanbul Medical Journal, vol.22, no.1, 2021, ss.61 - 67. 10.4274/imj.galenos.2021.45202 |
| AMA | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. İstanbul Medical Journal. 2021; 22(1): 61 - 67. 10.4274/imj.galenos.2021.45202 |
| Vancouver | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center. İstanbul Medical Journal. 2021; 22(1): 61 - 67. 10.4274/imj.galenos.2021.45202 |
| IEEE | Ahmadi P,Shirzad N,Shahsiah R,Hemmatabadi M "Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center." İstanbul Medical Journal, 22, ss.61 - 67, 2021. 10.4274/imj.galenos.2021.45202 |
| ISNAD | Ahmadi, Pouria vd. "Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center". İstanbul Medical Journal 22/1 (2021), 61-67. https://doi.org/10.4274/imj.galenos.2021.45202 |
